Author

M. Zureik

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Use of Sotatercept in France since Its Availability in June 2024: A Nationwide Study from the French Health Data System (SNDS).

BACKGROUND Pulmonary arterial hypertension (PAH) is a rare, severe and progressive disease associated with poor quality of life and high mortality. Sotatercept, a first-in-class fusion protein, has recently been shown to provide substantial clinical benefit as add-on therapy in PAH and was made available in France in 2...

Nazoiri Charifa, Alain Weill, M. Zureik et al. · Drugs - Real World Outcomes · 0 citations

Open access Oct 2026

Absolute and Relative Effectiveness of High-Dose vs Standard-Dose Influenza Vaccines Against Severe Outcomes in Older Adults

Importance Several influenza vaccine products are available for older adults, but evidence combining both their absolute effectiveness and head-to-head comparisons within the same large population remains scarce, limiting product-specific vaccination guidance for this high-risk group. Objective To estimate the relative...

S. Le Vu, N. Gutierrez-Melo, T. Cartailler et al. · medRxiv · 0 citations

Open access Aug 2026

Use, survival, and adverse events of dostarlimab monotherapy in advanced or recurrent endometrial cancer: a nationwide cohort study in France

Abstract Dostarlimab, a PD-1 inhibitor, was approved in Europe as monotherapy for patients with advanced or recurrent mismatch repair-deficient endometrial cancer, based on the phase I GARNET study. As real-world data remain limited, this study aimed to describe the characteristics and survival outcomes of patients tre...

A. Singier, Stéphane Vignot, D. Desplas et al. · The Oncologist · 0 citations